PREECLAMPSIA: NEW INFORMATION ABOUT THE PATHOGENESIS, DEFINITIONS AND RECOMMENDATIONS. REVIEW.
Background. Hypertensive disorders of pregnancy - chronic hypertension, gestational hypertension and preeclampsia - are a unique problem, since pathology and its therapeutic treatment simultaneously affect the mother and fetus, sometimes putting their well-being in conflict with each other. Preeclampsia, in particular, is one of the most dangerous complications of pregnancy. Often manifested as first-time hypertension and proteinuria during the third trimester of pregnancy, preeclampsia can rapidly progress to serious complications, including death of both mother and fetus. Although the cause of preeclampsia is still being debated, clinical and pathological studies show that the placenta plays a central role in the pathogenesis of this syndrome.
Aim. To review the scientific literature sources on the pathogenesis and treatment of preeclampsia.
Search strategy. In this review we search full-text publications in English and Russian, which are devoted to the pathogenesis and new recommendations for the treatment of preeclampsia. Next databases were used in the process of literature search: Pubmed, Web of science, Cyberleninka, Google Scholar by keywords. The search period was 2000-2022 years. 1566 publications were identified on this topic. 46 articles corresponded to our research objective. Inclusion criteria: Publications of the level of evidence A, B: meta-analyses, systematic reviews, cohort and cross-sectional studies. Exclusion criteria: summary reports, newspaper articles and personal messages.
Results and conclusions. Preeclampsia is the leading cause of maternal morbidity and mortality worldwide, the only definitive treatment for which - delivery of the fetus and placenta - leads to significant morbidity and mortality of newborns.
Aiganym R. Rash1,
Zaituna A. Khismetova2, https://orcid.org/0000-0001-5937-3045
Aglen T. Anissova1,
Kazbek A. Yermagambetov3
Nazym S. Iskakova1, https://orcid.org/0000-0001-5631-5499
1 Asfendiyarov Kazakh National Medical University, Almaty c., Republic of Kazakhstan;
2 NCJSC “Semey medical university”, Semey c., Republic of Kazakhstan;
3 Atyrau Regional Perinatal Center, Atyrau c., Republic of Kazakhstan
1. Aardema M. W. [et al.]. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses // Placenta. 2001. № 5 (22). C. 405–411.
2. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia // Circulation research. 2004. № 9 (95). C. 884–891.
3. Ahmed R. [et al.]. Pre-eclampsia and future cardiovascular risk among women: a review // Journal of the American College of Cardiology. 2014. № 18 (63). C. 1815–1822.
4. Amaral L. M. [et al.]. Preeclampsia: long-term consequences for vascular health // Vascular health and risk management. 2015. (11). C. 403–415.
5. Bellamy L. [et al.]. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis // BMJ (Clinical research ed.). 2007. № 7627 (335). C. 974–977.
6. Bokslag A. [et al.]. Preeclampsia; short and long-term consequences for mother and neonate // Early human development. 2016. (102). C. 47–50.
7. Broekhuijsen K. [et al.]. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial // Lancet (London, England). 2015. № 9986 (385). C. 2492–2501.
8. Cooper W. O. [et al.]. Major congenital malformations after first-trimester exposure to ACE inhibitors // The New England journal of medicine. 2006. № 23 (354). C. 2443–2451.
9. Dadelszen P. Von, Magee L. A., Roberts J. M. Subclassification of preeclampsia // Hypertension in pregnancy. 2003. № 2 (22). C. 143–148.
10. Davies E. L., Bell J. S., Bhattacharya S. Preeclampsia and preterm delivery: A population-based case-control study // Hypertension in pregnancy. 2016. № 4 (35). C. 510–519.
11. Dymara-Konopka W., Laskowska M., Oleszczuk J. Preeclampsia - Current Management and Future Approach // Current pharmaceutical biotechnology. 2018. № 10 (19). C. 786–796.
12. Espinoza J. [et al.]. Normal and abnormal transformation of the spiral arteries during pregnancy // Journal of perinatal medicine. 2006. № 6 (34). C. 447–458.
13. Gilbert J. S., Babcock S. A., Granger J. P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression // Hypertension (Dallas, Tex. : 1979). 2007. № 6 (50). C. 1142–1147.
14. Goldenberg R. L. [et al.]. Epidemiology and causes of preterm birth // Lancet (London, England). 2008. № 9606 (371). C. 75–84.
15. Harmon Q. E. [et al.]. Risk of fetal death with preeclampsia // Obstetrics and gynecology. 2015. № 3 (125). C. 628–635.
16. Heida K. Y. [et al.]. Earlier Age of Onset of Chronic Hypertension and Type 2 Diabetes Mellitus After a Hypertensive Disorder of Pregnancy or Gestational Diabetes Mellitus // Hypertension (Dallas, Tex. : 1979). 2015. № 6 (66). C. 1116–1122.
17. Hermes W. [et al.]. Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study // American journal of obstetrics and gynecology. 2013. № 6 (208). C. 474.e1-474.e8.
18. Karumanchi S. A. [et al.]. Preeclampsia: a renal perspective // Kidney international. 2005. № 6 (67). C. 2101–2113.
19. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia // Biology of reproduction. 2003. № 1 (69). C. 1–7.
20. Koopmans C. M. [et al.]. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial // Lancet (London, England). 2009. № 9694 (374). C. 979–988.
21. Levine R. J. [et al.]. Circulating angiogenic factors and the risk of preeclampsia // The New England journal of medicine. 2004. № 7 (350). C. 672–683.
22. Li D. K. [et al.]. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study // BMJ (Clinical research ed.). 2011. № 7829 (343).
23. Lin Y. S. [et al.]. Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan // The American journal of cardiology. 2011. № 2 (107). C. 325–330.
24. Lisonkova S. [et al.]. Maternal morbidity associated with early-onset and late-onset preeclampsia // Obstetrics and gynecology. 2014. № 4 (124). C. 771–781.
25. Lykke J. A. [et al.]. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother // Hypertension (Dallas, Tex. : 1979). 2009. № 6 (53). C. 944–951.
26. Magnussen E. B. [et al.]. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors // Obstetrics and gynecology. 2009. № 5 (114). C. 961–970.
27. Makris A. [et al.]. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1 // Kidney international. 2007. № 10 (71). C. 977–984.
28. Masuyama H. [et al.]. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia // BJOG : an international journal of obstetrics and gynaecology. 2010. № 3 (117). C. 314–320.
29. Moldenhauer J. S. [et al.]. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent // American journal of obstetrics and gynecology. 2003. № 4 (189). C. 1173–1177.
30. Mongraw-Chaffin M. L., Cirillo P. M., Cohn B. A. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort // Hypertension (Dallas, Tex. : 1979). 2010. № 1 (56). C. 166–171.
31. Murphy D. J., Stirrat G. M. Mortality and morbidity associated with early-onset preeclampsia // Hypertension in pregnancy. 2000. № 2 (19). C. 221–231.
32. Ness R. B., Sibai B. M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia // American journal of obstetrics and gynecology. 2006. № 1 (195). C. 40–49.
33. Ødegård R. A. [et al.]. Preeclampsia and fetal growth // Obstetrics & Gynecology. 2000. № 6 (96). C. 950–955.
34. Papageorghiou A. T. [et al.]. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation // Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2001. № 5 (18). C. 441–449.
35. Papageorghiou A.T. [et al.]. Second-trimester uterine artery Doppler screening in unselected populations: a review // The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2002. № 2 (12). C. 78–88.
36. Papageorghiou A.T., Campbell S. First trimester screening for preeclampsia // Current opinion in obstetrics & gynecology. 2006. № 6 (18). C. 594–600.
37. Paruk F., Moodley J. Maternal and neonatal outcome in early- and late-onset pre-eclampsia // Seminars in neonatology : SN. 2000. № 3 (5). C. 197–207.
38. Pinheiro M. B., Gomes K. B., Dusse L. M. S. Fibrinolytic system in preeclampsia // Clinica chimica acta; international journal of clinical chemistry. 2013. (416). C. 67–71.
39. Rana S. [et al.]. Preeclampsia: Pathophysiology, Challenges, and Perspectives // Circulation research. 2019. № 7 (124). C. 1094–1112.
40. Roberts J. M., Hubel C. A. The two stage model of preeclampsia: variations on the theme // Placenta. 2009. № Suppl A (30 Suppl A). C. 32–37.
41. Saigal S., Doyle L. W. An overview of mortality and sequelae of preterm birth from infancy to adulthood // Lancet (London, England). 2008. № 9608 (371). C. 261–269.
42. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia // Lancet (London, England). 2005. № 9461 (365). C. 785–799.
43. Sircar M., Thadhani R., Karumanchi S.A. Pathogenesis of preeclampsia // Current opinion in nephrology and hypertension. 2015. № 2 (24). C. 131–138.
44. Stillman I. E., Karumanchi S. A. The glomerular injury of preeclampsia // Journal of the American Society of Nephrology : JASN. 2007. № 8 (18). C. 2281–2284.
45. Veerbeek J.H.W. [et al.]. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension // Hypertension (Dallas, Tex. : 1979). 2015. № 3 (65). C. 600–606.
46. Vikse B.E. [et al.]. Preeclampsia and the risk of end-stage renal disease // The New England journal of medicine. 2008. № 8 (359). C. 800–809.
Количество просмотров: 280
Категория статей:
Обзор литературы
Библиографическая ссылка
Rash A.R., Khismetova Z.A., Anissova A.T., K.A. Yermagambetov, N.S. Iskakova Preeclampsia: new information about the pathogenesis, definitions and recommendations. Review // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 4, pp. 224-230. doi 10.34689/SH.2022.24.4.027Похожие публикации:
ДИАГНОСТИЧЕСКАЯ И ТЕРАПЕВТИЧЕСКАЯ ЛАПАРОСКОПИЯ ПРИ ТРАВМАХ ЖИВОТА. ОБЗОР ЛИТЕРАТУРЫ.
КАЧЕСТВО ЖИЗНИ И МЕТОДЫ ЕГО ОЦЕНКИ ПРИ ПЕРВИЧНОМ БИЛИАРНОМ ХОЛАНГИТЕ
ЛЕКАРСТВЕННО-ИНДУЦИРОВАННЫЕ ПОРАЖЕНИЯ ПЕЧЕНИ И ГЕНДЕРНЫЕ РАЗЛИЧИЯ
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
НОВЫЕ СИНДРОМЫ И ПАТТЕРНЫ ОСТРОЙ ОККЛЮЗИИ КОРОНАРНЫХ АРТЕРИЙ. ОБЗОР ЛИТЕРАТУРЫ.